The development of small-molecule PTPN2 inhibitors such as those described here will enable further study of the mechanism by which PTPN2 inhibition sensitizes resistant tumors to immunotherapy beyond melanoma and colorectal cancer. Here, PTPN2 is linked to melanoma.